We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Read MoreHide Full Article
Adaptive Biotechnologies (ADPT - Free Report) shares soared 12.5% in the last trading session to close at $11.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.5% gain over the past four weeks.
The sudden rise in price can be attributed to investor optimism related to growing demand and volume growth of Adaptive Biotechnologies’ clonoSEQ, an FDA-cleared diagnostic test used to detect and monitor minimal residual disease (MRD) in patients with certain types of blood cancers.
This life-sciences research company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +7.7%. Revenues are expected to be $49.7 million, up 15.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Adaptive Biotechnologies, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ADPT going forward to see if this recent jump can turn into more strength down the road.
Adaptive Biotechnologies is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Fortrea Holdings Inc. (FTRE - Free Report) , finished the last trading session 2.4% lower at $5.19. FTRE has returned 28% over the past month.
Fortrea Holdings Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.06. Compared to the company's year-ago EPS, this represents a change of +300%. Fortrea Holdings Inc. currently boasts a Zacks Rank of #2 (Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
Adaptive Biotechnologies (ADPT - Free Report) shares soared 12.5% in the last trading session to close at $11.98. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 16.5% gain over the past four weeks.
The sudden rise in price can be attributed to investor optimism related to growing demand and volume growth of Adaptive Biotechnologies’ clonoSEQ, an FDA-cleared diagnostic test used to detect and monitor minimal residual disease (MRD) in patients with certain types of blood cancers.
This life-sciences research company is expected to post quarterly loss of $0.24 per share in its upcoming report, which represents a year-over-year change of +7.7%. Revenues are expected to be $49.7 million, up 15.1% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Adaptive Biotechnologies, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ADPT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Adaptive Biotechnologies is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Fortrea Holdings Inc. (FTRE - Free Report) , finished the last trading session 2.4% lower at $5.19. FTRE has returned 28% over the past month.
Fortrea Holdings Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.06. Compared to the company's year-ago EPS, this represents a change of +300%. Fortrea Holdings Inc. currently boasts a Zacks Rank of #2 (Buy).